Condition
Recurrent Kidney Wilms Tumor
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774 · 2020-10-13
ACTIVE_NOT_RECRUITINGPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250 · 2018-08-13
COMPLETEDLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)NCT03213704 · 2017-08-23
ACTIVE_NOT_RECRUITINGCommon interventions
Biospecimen CollectionPROCEDURE1Bone Marrow Aspiration and BiopsyPROCEDURE1Bone ScanPROCEDURE1Computed TomographyPROCEDURE1Laboratory Biomarker AnalysisOTHER1Larotrectinib SulfateDRUG1Magnetic Resonance ImagingPROCEDURE1PalbociclibDRUG1Pharmacological StudyOTHER1Radionuclide ImagingPROCEDURE1TipifarnibDRUG1X-Ray ImagingPROCEDURE1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING2
COMPLETED1
Phase mix
PHASE23
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.